Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

According to the National Family Health Survey-5 (2019–21), 24% of Indian women and 23% of Indian men are either overweight ...

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...